Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by francois21on May 28, 2012 6:23pm
276 Views
Post# 19954054

RE: Albiglutide

RE: Albiglutide

Better deal than we think?

 

Well, the documents of Novozyme talking about Albupure used for Albiglutide in GSK diabete drug gave me an hint about the possible client of PLI.

 

However, I'm pretty sure GSK still the client, but also that it's not only albupure used in the product.

 

1. The collaboration with Novozyme on Albupure was announced in 2010.

2. In 2004, there was a NR about GSK and PLI regarding some specific ligands. About 1 year later, GSK716155, (if I'm not mistaken, it's albiglutide) strat his first clinical trial in phase I. It's highly possible that another ligand made by PLI is used in manufacturing.

 

So, if the clinical trial started before the collaborative agreement with Novozymes, we are dealing with something else. And this open more the door for a locked in  ligand deal à la Celgene.

 

This will be a very interesting story to follow.

Bullboard Posts